

AMENDMENTS TO THE CLAIMS:

1-7. (Canceled)


8. (Previously Presented) A pharmaceutical composition comprising one or more pharmaceutically acceptable carriers and/or diluents and, as the active principle, a compound as defined in claim 12.

9. (Previously Presented) A compound as defined in claim 12 for use in a method of treatment of a human or animal body by therapy.

10. (Original) A compound as claimed in claim 9 for use as an antitumour agent.

11. (Previously Presented) A method of manufacturing a medicament for use as an antitumor agent comprising utilizing a compound as defined in claim 12.

12. (Currently Amended) A compound which is an acryloyl substituted distamycin derivative of formula



wherein:

n is 2, 3 or 4;


m is 1 or 2;

X and Y are the same or different and are selected, independently for each heterocyclic ring of the polyheterocyclic chain, from N and CH;

R₁ and R₂ are both hydrogen atoms;

R₃ is hydrogen or halogen;

B is selected from



or a pharmaceutically acceptable salt thereof;

provided that

X and Y are not both N for the same heterocyclic ring.


13. (New) A compound according to claim 12 wherein
n is 3 or 4;
m is 1; and
R₃ is chlorine or bromine.

14. (New) A compound selected from the group consisting of:
3 - (1-methyl-4-(1-methyl-4-(1-methyl-4-(1-methyl-3-(α -bromoacrylamido)-pyrazole-5-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido) propioncyanamidine;
3 - (1-methyl-4-(1-methyl-4-(1-methyl-4-(1-methyl-3-(α -bromoacrylamido) pyrazole-5-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido) propion-N-methylamidine;
3 - (1-methyl-4-(1-methyl-4-(1-methyl-4-(1-methyl-3-(α -chloroacrylamido) pyrazole-5-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido) propion-N-methylamidine;
3 - (1-methyl-4-(1-methyl-4-(1-methyl-3-(1-methyl-3-(α -bromoacrylamido) pyrazole-5-carboxamido) pyrazole-5-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido) propion-N-methylamidine;
3 - (1-methyl-4-(1-methyl-4-(1-methyl-3-(1-methyl-3-(α -chloroacrylamido) pyrazole-5-carboxamido) pyrazole-5-carboxamido) pyrrole-2-carboxamido) pyrrole-2-carboxamido) propion-N-methylamidine;
3 - (1-methyl-4-(1-methyl-4-(1-methyl-4-(1-methyl-3-(α -bromoacrylamido) pyrazole-5-carboxamido) imidazole-2-carboxamido) pyrrole-2-carboxamido) pyrrole-2-

carboxamido) propion-N-methylamidine;
 3 - (1-methyl-4-(1-methyl-4-(1-methyl-3-(α -bromoacrylamido) pyrazole-5-carboxamido)
 pyrrole-2-carboxamido) pyrrole-2-carboxamido) propioncyanamidine;
 3 - (1-methyl-4-(1-methyl-4-(1-methyl-3-(α -bromoacrylamido) pyrazole-5-carboxamido)
 pyrrole-2-carboxamido) pyrrole-2-carboxamido) propion-N-methylamidine;
 3 - (1-methyl-4-(1-methyl-4-(1-methyl-3-(α -chloroacrylamido) pyrazole-5-carboxamido)
 pyrrole-2-carboxamido) pyrrole-2-carboxamido) propion-N-methylamidine; and the
 pharmaceutically acceptable salts thereof.

15. (New) A process for preparing a compound as defined in claim 12,
 which process comprises:


(a) reacting a compound of formula:



wherein n, m, and B are as defined in claim 1;

p is 0 or 1;

with a compound of formula:




wherein R_1 , R_2 , and R_3 , are as defined in claim 1;

p is as defined above;

z is hydroxy or a leaving group;

or:

(b) when B is equal to $-C\equiv N$, reacting a compound of formula:



wherein n , m , R_1 , R_2 , and R_3 , are as defined above;

with succinic anhydride; and,

(c) if desired, converting a compound of formula (I) into a pharmaceutically acceptable salt thereof.